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Abstract:
Objective:
Host derived markers on virally infected cells or virions may provide targets for the generation of antiviral agents. Recently, we
identified phosphatidylserine (PS) as a host marker of virions and virally-infected cells.
Methods and Materials:
Under normal physiological conditions, PS is maintained on the inner leaflet of the plasma membrane facing the cytosol. Following
viral infection, activation or pre-apoptotic changes cause PS to become externalized. We have previously shown that bavituximab, a
chimeric human-mouse antibody that binds PS complexed with β2-glycoprotein I (β2GP1), protected rodents against lethal Pichinde
virus and cytomegalovirus infections.
Results:
Here, we determined the antiviral activity of a fully human monoclonal antibody, PGN632, that directly binds to PS. Treatment with
PGN632 protected 20% of guinea pigs with advanced infections of the hemorrhagic arenavirus, Pichinde, from death. Combining
PGN632 with ribavirin improved the antiviral activity of both agents, such that the combination rescued 50% of animals from death.
Conclusion:
The major mechanisms of action of PGN632 appear to be opsonization of virus and antibody-dependent cellular cytotoxicity of
virally-infected cells. PS-targeting agents may have utility in the treatment of viral diseases.
Keywords: Anti-phosphatidylserine, Hemorrhagic arenavirus infection, Phosphatidylserine, Pichinde virus, Cellular cytotoxicity.
1. INTRODUCTION
Pichinde virus is a small, negative sense RNA virus among a diverse group of arenaviruses including Lassa virus,
Junin  virus,  and  Machupo  virus  capable  of  causing  viral  hemorrhagic  fever  (VHF)  in  humans  [1,  2].  Due  to  the
biodefense and public health risks associated with these viruses, the National Institutes for Health have classified these
pathogens  as  category  A  agents.  In  spite  of  the  threat  posed  by  arenaviruses,  no  vaccines  against  them have  been
approved  for  human  use,  and  the  only  approved  antiviral  agent  is  ribavirin  [2].  While  ribavirin  has  demonstrated
efficacy in  patients,  concerns over  toxicity  in  humans have limited its  usage.  In  addition,  ribavirin  may drive viral
evolution [3], giving rise to drug-resistant strains which further complicate viral clearance. It is  therefore  important  to
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University Blvd Edinburg, Texas 78539, USA, Tel: 956 665-7147; Fax: 956 665-3657; E-mails: john.thomas@utrgv.edu; thomjohn3@gmail.com
304   The Open Microbiology Journal, 2017, Volume 11 Thomas and Thorpe
develop broad-spectrum antiviral  agents  that  target  the virus and virally-infected cells  without  contributing to viral
resistance.
Bavituximab  is  a  novel  therapeutic  antibody  that  has  been  shown  to  have  activity  [4]  against  the  arenavirus,
Pichinde  virus, which causes a  lethal disease in  guinea pigs  that closely models  that caused by Lassa virus in humans
[5, 28]. Bavituximab is a chimeric monoclonal antibody consisting of murine VH and Vκ chains linked to human IgG1
constant domains. It targets a lipid, phosphatidylserine (PS), which is normally intracellular [6, 7], but becomes exposed
on the outer membrane surface of virally-infected cells and on enveloped virions. Bavituximab binds with high affinity
to PS complexed with the PS-binding plasma protein β2GP1 [8]. Administration of bavituximab to guinea pigs with
advanced Pichinde virus infections enabled the animals to overcome their infections and recover [4]. Bavituximab acted
by directly  clearing opsonized virions from the bloodstream, and by eliminating virally-infected cells  by antibody-
dependent cellular cytotoxicity (ADCC). Bavituximab also bound to cells infected with multiple viruses, and rescued
mice from lethal murine cytomegalovirus (mCMV) infection [4]. Pilot clinical trials in patients co-infected with chronic
Hepatitis  C  virus  and  human  immunodeficiency  virus  have  shown  that  treatment  with  bavituximab  appears  well-
tolerated with signs of reductions in virus load in the blood [9].
A series of fully human PS-targeting antibodies was generated by phage display technology to further explore the
antiviral activity of PS-targeting antibodies. One of the antibodies, PGN632, was selected for its ability to bind directly
to PS. An antibody that binds to PS without the requirement for β2GP1 has advantages in that it should not deplete
β2GP1 from the blood,  possibly giving a more robust  antiviral  effect  not  compounded by the clearance kinetics  of
β2GP1. Further, it is theoretically possible that an antibody such as PGN632 which does not require β2GP1-mediated
interactions may be positioned closer to the viral envelope or surface of the cell, thus facilitating ADCC or interference
with viral entry. The purpose of this study was to examine the efficacy and mode of action of PGN632 in the guinea pig
Pichinde virus model.
2. MATERIALS AND METHODS
2.1. Antibodies
PGN632  and  bavituximab  were  produced  under  serum  free  conditions  by  Avid  Bioservices,  a  subsidiary  of
Peregrine Pharmaceuticals, Inc., Tustin, CA. Erbituximab (or Rituximab) was purchased from the UT Southwestern
pharmacy,  and  is  a  chimeric  human-mouse  IgG1  monoclonal  antibody  which  was  used  as  a  negative  control.  The
PGN632 antibody was generated by Peregrine in collaboration with Affitech AG, Oslo, Norway. It is a fully human Vλ
IgG1 that binds directly to PS with a KD in the low nM range as determined by Biacore analyses. Bavituximab is a
chimeric antibody consisting of mouse VH and Vκ chains linked to human IgG1 constant domains and binds to human
β2GP1:PS complexes with a KD of 0.4nM.
2.2. Cells and Media
Vero-76  cells  (CCL81;  ATCC)  were  maintained  in  RPMI  1640  medium  (Sigma-Alrdich),  supplemented  with
antibiotics and 10% fetal bovine serum (Gibco). JH4 clone 1 (CCL158; ATCC) was the source of guinea pig fibroblasts
used  in  the  mechanistic  studies.  Fibroblasts  were  cultured  in  Ham's  F12K  medium  (Gibco),  supplemented  with
antibiotics and 10% fetal bovine serum (Gibco).
2.3. Viruses
Natural isolates of Pichinde virus are non-pathogenic in guinea pigs however, serially passaging Pichinde virus in
guinea pigs has shown that more virulent strains can be generated which are lethal in the guinea pig model [5 - 28].
Using Pichinde virus CoAn 4763-P16 (generously provided by Dr. Judith Aronson at UTMB) as a starting inoculum,
groups of Hartley guinea pigs (n=5) were inoculated intraperitoneally (i.p.) with 1 ml of virus. On day 6 post infection,
spleens were harvested, pooled, and 10% (w/v) homogenates were prepared in RPMI 1640 media. These stocks were
aliquoted and stored at -80C, and clarified by centrifugation before use. This initial Pichinde virus inoculum (P17) was
then  used  as  source  material  for  another  in  vivo  passaging  experiment  that  generated  a  P18  isolate,  and  lastly  we
repeated the in vivo passaging one more time, thus generating a P19 isolate, termed Pichinde virus CoAn 4763-P19.
Hereafter, when the term Pichinde virus is used within the context of our experimental studies, we are referring to the
P19 isolate. This virus was quantitated by plaque assay on Vero cells, and used as our viral challenge stock for all in
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vivo and in vitro experiments. Viral titers of spleen stocks ranged between 106 and 107 plaque-forming units (PFU)/ml
of homogenate.
2.4. Immunofluorescence Staining
Vero-76 cells were grown on chamber slides (BD Biosciences, San Jose, CA), and infected with Pichinde virus at a
multiplicity  of  infection  (MOI)  of  5.0.  At  48  hours  post-infection,  infected  and  uninfected  cells  were  stained  with
PGN632 in the presence of β2GP1 at 37°C. Bavituximab and erbituximab were used as positive and negative controls,
respectively. The cells were fixed in 4% paraformaldehyde, and incubated with anti-human FITC-conjugated antibodies
(Jackson Immunoresearch, West Grove, PA). Cells were permeabilized with 0.1% Triton-X100. The cytoskeleton was
stained  with  Texas  red-phalloidin  (Fisher  Scientific  Inc.,  Carlsbad,  CA);  nuclei  were  stained  with  Hoescht  33342
(Invitrogen, Grand Island, NY). Images were captured using a Coolsnap digital camera, and analyzed with MetaVue
software (MDS Analytical Technologies Inc., Sunnyvale, CA).
2.5. Antibody Interactions with Virions or Virally-Infected Cells
For virus ELISAs, Immunolon U-bottom plates were coated with 100µl (approximately 106 PFU) of Pichinde virus,
and  incubated  at  4°C  overnight.  The  next  day,  plates  were  washed  and  blocked  with  Superblock  (Thermo  Fisher
Scientific  Inc.,  Rockford,  IL)  supplemented  with  1%  BSA  (Gibco).  PGN632,  bavituximab  (positive  control)  and
erbituximab (negative control) at 100µg/ml were mixed with 100µg/ml of human β2GP1 and serial ten-fold dilutions
were  performed  along  the  plate.  Binding  was  detected  with  an  HRP-conjugated  secondary  antibody  (Jackson
Immunoresearch,  West  Grove,  PA)  and  substrate  O-phenylenediamine  dihydrochloride  (Sigma-Aldrich,  St.  Louis,
MO). Absorbance was measured at 490nm.
To detect binding of PGN632 to Pichinde virus, Magprep anti-human IgG magnetic beads (Qiagen Inc., Valencia,
CA)  were  coated  with  PGN632,  bavituximab,  or  erbituximab.  Streptavidin-coated  Magprep  beads  (Qiagen  Inc.,
Valencia, CA) were coated with biotinylated antibodies to guinea pig IgG and guinea pig antibodies to Pichinde virus in
the presence of human β2GP1 (1µg/ml) at 37°C on a rotator for one hour. Next, we added 500 PFU of Pichinde virus to
the beads, and incubated them for 30 minutes at room temperature. After this, beads and bound virus were removed
using  a  magnet,  and  the  remaining  virus  was  quantified  by  plaque  assay.  The  percentage  removal  of  virus  was
calculated.
2.6. Phospholipid Specificity
Phospholipids  (Avanti  Polar  Lipids,  Inc.)  were  re-suspended  in  n-Hexane  (Sigma-Aldrich,  St.  Louis,  MO)  and
coated onto Immunolon U-bottom plates at 10µg/ml. Plates were washed, blocked and PGN632, in the presence or
absence of β2GP1, was added to each plate at 100µg/ml. Serial ten-fold dilutions were performed, and goat-anti-human
HRP-conjugated  secondary  antibody  and  substrate  O-phenylenediamine  dihydrochloride  was  used  to  detect  bound
PGN632. Reactions were stopped with 0.18M Na2HSO4, and absorbance was measured at 490nm [29].
2.7. Therapy Studies
Male Hartley guinea pigs (Charles River Laboratories International, Inc., Wilmington, MA) were infected i.p. with
105 PFU of Pichinde virus isolate CoAn 4763-P19. This dose is equivalent to approximately 1000 lethal doses of virus.
Animals were weighed and monitored daily for body temperature and physical appearance. Treatment was begun when
signs of disease appeared, usually four days post-infection (animals had pyremia (>39ºC), had lost body weight and had
disheveled  fur).  For  single  agent  therapy,  animals  were  treated  i.p.  with  PGN632,  bavituximab,  or  erbituximab  at
6mg/kg per treatment, three times a week, for a maximum total of 12 doses. For combination therapy, animals were
treated with antibody plus 3.25 mg/kg of ribavirin i.p. daily for a maximum of 10 doses
2.8. Virus Load Analyses
Guinea pigs were infected i.p. with a lethal dose of Pichinde virus. After the onset of disease signs (usually four
days post-infection), animals were treated for one week with 6 mg/kg i/p. of PGN632, bavituximab, or erbituximab on
days 7, 9, and 11. Groups of animals were sacrificed on days 10 and 14. Blood and major organs were collected and
frozen. Tissues were homogenized and virus was quantified by plaque assay.
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2.9. PT and aPTT Studies
To assess the effect of PGN632 on coagulation parameters, uninfected male guinea pigs were treated with 6 mg/kg
i.p.  of  PGN632,  bavituximab,  or  erbituximab.  At  24  hours  after  treatment,  citrated  blood  samples  were  collected.
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were determined for recalcified blood samples
by Antech Diagnostics (Fort Worth, TX).
2.10. Antibody-Mediated Cellular Ccytotoxicity
Guinea pig fibroblasts were used as target cells, and peritoneal exudate cells from thioglycollate-treated guinea pigs
were used as effector cells. Fibroblasts were obtained from ATCC as described above, and peritoneal exudate cells were
obtained  by  injecting  guinea  pigs  i.p.  with  15.0  ml  of  3%  thioglycollate  medium  (BD  Difco).  Four  days  after  the
injection, peritoneal exudate cells were harvested by aspirating the fluid from the peritoneal cavity. After removal of the
contaminating tissue debris by cell strainer, red blood cells in the cell suspension were lysed with ammonium chloride
solution. Cells were cultured in DMEM medium (Gibco), supplemented with 10% fetal bovine serum and antibiotics for
2 hours. Non-adherent cells were removed, and the adherent cells were collected and used for experiments. To measure
antibody-mediated  cellular  cytotoxicity,  fibroblasts  were  infected  with  Pichinde  virus  at  an  MOI  of  5.0.  PGN632,
bavituximab, or erbituximab (20 µg/ml) in the presence of β2GP1 were added to the target cells 24 hours after infection.
Effector cells were added to the cell cultures 48 hours after infection. Cytotoxicity was determined 18 hours later using
a CytoTox 96 non-radioactive assay (Promega Corporation, Madison, MI) to determine cell vibility in antibody-treated
versus untreated cell cultures.
2.11. Opsonization of virus
Guinea pigs were infected i.p. with 105 PFU of Pichinde virus. After the onset of disease signs (usually four days
post-infection),  animals  were  treated  with  a  single  dose  of  PGN632,  bavituximab,  or  erbituximab  (6  mg/kg,  i.p.).
Animals were sacrificed 24 hours later, and whole blood was collected. The amount of virus present in the blood was
quantified by plaque assay.
2.12. Virus-Specific Humoral Responses
Guinea pig sera from infected and treated animals were analyzed for the presence of virus-specific antibodies by
ELISA. Immunolon U-bottom plates were coated with 100µl (approximately 106 PFU) of Pichinde virus, and incubated
at  4°C  overnight.  The  next  day,  plates  were  washed  and  blocked  with  Superblock  (Thermo  Fisher  Scientific  Inc.,
Rockford, IL) supplemented with 1% BSA (Gibco). Plates were then incubated with guinea pig sera, and binding was
detected with an HRP-conjugated goat anti-guinea pig antibody (Jackson Immunoresearch, West Grove, PA). Substrate
O-phenylenediamine dihydrochloride (Sigma-Aldrich, St. Louis, MO) was added; absorbance was measured at 490nm.
2.13. Proliferative Responses to Viral Antigen
Antigen-specific immune responses were analyzed using a 3H-thymidine incorporation assay [4]. Briefly, animals
were  challenged  i.p.  with  a  lethal  dose  of  Pichinde  virus.  After  onset  of  disease  signs  at  four  days  post-challenge,
animals were treated with 4 doses of PGN632, bavituximab, or erbituximab (6 mg/kg, i.p.) given every 2 days for 8
days. Fourteen days after challenge, splenocytes were harvested and seeded at a density of 5 x 104 cells per well in
RPMI 1640 medium containing antibiotics and 10% FBS in round bottom 96-well plates (Thermo Fisher Scientific Inc.,
Rockford, IL). Splenocytes were stimulated with either extracellular viral antigen (10 µg/ml) obtained from multiple
freeze-thawed viral stocks or mock antigen for 48 hours [4]. On day 3, cells were collected, washed, and pulsed with
1µCi per well of 3[H]-thymidine for eight hours (Amersham Biosciences Corporation, Piscataway, NJ). Stimulation
index was calculated.
2.14. Statistical Analyses
The significance between two means (histograms) was calculated by student’s unpaired t-test. Log-rank analysis for
non-normally distributed data (JMP SAS v12, Cary, NC) was used to compare the survival of the animals exposed to
different treatments, and pairwise comparisons of treatment means were made between groups to determine statistical
significance. Chi-square, degrees of freedom, and p values are reported. A value was considered significant if p ≤ 0.05.
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2.15. Animal Usage
Male Hartley guinea pigs (Charles River Laboratories International, Inc., Wilmington, MA), aged 4-6 weeks, and
approximately  300-350g  in  weight,  were  used  for  all  animal  studies.  The  animals  were  maintained  in  a  specific
pathogen free (SPF) BSL3 facility, and fed a normal diet of pig chow and water (unrestricted access to both). Prior to
each animal  experiment,  guinea  pigs  were  randomized and grouped,  weighed,  and sub-cutaneously  implanted with
biometric transponder chips that recorded identification number and temperature (Bio Medic Data Systems, Seaford,
DE). Infected and/or antibody-treated animals were monitored twice daily for the entire duration of the experiment.
Animals were euthanatized when their body weight decreased by 20% of their total body weight, or when they were
scored as ‘severe’ based upon appearance, clinical signs, or unprovoked behavior in accordance with UT Southwestern
Institutional Animal Care and Use Committee guidelines.
3. RESULTS
3.1. Recognition of PS is β2GP1 independent
PGN632  bound  directly  to  PS-coated  microplates.  50%  maximal  binding  was  observed  with  PGN632  at  a
concentration of 0.2 µg/ml (1.3nM) (Fig. 1). Binding was not increased in the presence of human β2GP1 (not shown).
Binding was also not due to carryover of trace amounts of contaminating β2GP1, which has confounded other studies
[10,  11],  since the antibodies were produced under serum free conditions.  PGN632 bound directly to other anionic
phospholipids including phosphatidylglycerol (PG), cardiolipin (CL), phosphatidylinositol (PI), and phosphatidic acid
(PA) (Fig. 1). PGN632 did not recognize any of the neutral phospholipids, sphingomyelin (SM), phosphatidylcholine
(PC), or phosphatidylethanolamine (PE).
Fig.  (1).  ELISA  detection  of  PGN632  binding  to  immobilized  PS.  Antibody  was  added  to  ELISA  plates  coated  with  various
phospholipids. Serial ten-fold dilutions of the antibodies were prepared. Plates were developed with HRP-labeled anti-human IgG
followed by O-phenylenediamine dihydrochloride and the absorbance read at 490nm. PS, phosphatidylserine; CL, cardiolipin; PI,
phosphatidylinositol; PA, phosphatidic acid; PG, phosphatidylglycerol; PC, phosphatidylcholine; PE, phosphatidylethanolamine;
SM, sphingomyelin. Points; means of triplicate determinations.
3.2. PGN632 Binds to Virally-Infected Cells
Immunofluorescence microscopy showed that  PGN632 bound specifically to cells  infected with Pichinde virus.
Uninfected Vero cells were not visibly stained. After infection, the cells developed the same punctate staining pattern
that we have previously observed with bavituximab on virally infected cells [4]. By 24-48 hours after infection, there
was prominent staining of bleb-like structures on the surface of the cells, and weaker staining was visible over the entire

























308   The Open Microbiology Journal, 2017, Volume 11 Thomas and Thorpe
3.3. PGN632 Binds to Virions
PGN632  bound  specifically  to  Pichinde  virions  adsorbed  onto  ELISA plates.  The  binding  of  the  PGN632  was
antigen-specific, since the erbituximab control antibody did not bind to the virions. PGN632 and bavituximab showed
the same ability to bind to the immobilized virions (Fig. 3a). To confirm that the PGN632 could bind to live infectious
virions, bead depletion assays were performed in which magnetic beads coated with PGN632 were used to pull down
infectious virus, and the number of infectious virus particles remaining in suspension were quantified by plaque assay.
PGN632-coated  beads  removed 80% of  the  infectious  virons,  the  same as  for  bavituximab-coated  beads  (Fig.  3b).
Erbituximab-coated  beads  did  not  remove  the  virions,  showing  that  the  depletion  caused  by  the  PGN632-  and
bavituximab-coated beads was antigen specific. A further control compared the depletion with that of beads coated with
polyclonal guinea pig IgG purified from guinea pigs that had been immunized with Pichinde virus. The polyclonal anti-
Pichinde virus-coated beads removed the same amount of virus from the suspensions as did the PGN632-coated beads
(Fig. 3b). Thus, PGN632 is capable of binding to PS on the external surface of the Pichinde virus envelope, at levels
similar to those seen with bavituximab.
Fig. (2). PGN632 binds to Pichinde virus-infected cells. Immunofluorescence staining of uninfected Vero cells (top panels) and
Pichinde virus-infected cells (bottom panels) with antibody (green) 48h after infection. Cytoskeleton is stained red; nuclei are blue.
Bavituximab/β2GP1 was used as a positive control and erbituximab as a negative control.
Fig. (3). PGN632 binding to Pichinde virus. (a) ELISA: Pichinde virus was coated onto 96-well plates. Antibody (1μg/ml) was added
in the presence of  β2GP1 (1µg/ml)  to enable binding of  bavituximab.  Columns,  mean absorbance (n=3);  error  bars,  S.E.M. (b)
Depletion of infectious Pichinde virus by PGN632-coated magnetic beads. Beads coated with bavituximab or guinea pig antibodies
to Pichinde virus (anti-PV) were used as positive controls. β2GP1 (1µg/ml) was added to enable binding of bavituximab. Beads
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3.4. PGN632 is Well-Tolerated in Vivo
Uninfected guinea pigs treated with PGN632 (6 mg/kg, i.p., three times a week) gained body weight at the same rate
as untreated animals. Their physical activity and appearance were indistinguishable from untreated animals. Because
PGN632 binds to PS, it has the potential to be anti-coagulating through interference with coagulation factor binding to
PS surfaces. We therefore measured PT and aPTT of blood drawn from uninfected guinea pigs 6 hours and 24 hours
after treatment with PGN632 (6 mg/kg, i.p.). Neither PT nor aPTT in PGN632-treated animals was prolonged relative to
erbituximab-treated or bavituximab-treated animals. (data not shown).
3.5. PGN632 Therapy Combined with Ribavirin Protects Guinea Pigs from Advanced Pichinde Virus Infection
Guinea pigs  were  infected with  105  PFU (approximately  103  lethal  doses)  of  Pichinde virus,  and treatment  was
begun when they showed signs of advanced infection (body temperature >39ºC, weight loss, disheveled appearance).
When administered as a single agent, PGN632 protected 20% of guinea pigs from dying from their infections, the same
percentage as for bavituximab (Fig. 4a). While notable, the difference in survival between groups treated with anti-PS
antibody and the PBS control animals was not significant (p = 0.1189). The guinea pigs started to regain body weight
and gradually returned to having normal physical signs over the following 10-12 days. As expected, animals treated
with erbituximab were not protected from challenge and did not survive past day 15.
Fig.  (4).  Survival  of  guinea  pigs  after  lethal  infection  with  Pichinde  virus  and  PGN632  therapy  and/or  ribavirin.  (a)  Without
ribavirin: guinea pigs (n=10) were infected with 105 PFU of Pichinde virus (approx. 103 lethal doses) and, starting 4 days later, were
treated with PGN632 (6 mg/kg) i.p. three times a week for up to 3 weeks. X2 = 5.8543; degrees freedom = 3; p = 0.1189. (b) With
ribavirin: the experiment was performed as in (a) except that the guinea pigs also received ribavirin (3.25 mg/kg, i.p.) daily for 10
days. Bavituximab was used as a positive control and erbituximab as a negative control. Surviving guinea pigs were re-challenged
with 105 PFU of Pichinde virus i.p. on day 60 (a) or day 90 (b) and were immune. The results are representative of two separate
experiments. X2 = 14.6542; degrees freedom = 4; p = 0.0055.
We next determined if PGN632 offered better protection when given in combination with ribavirin, the primary
drug for treating Lassa virus infection. Animals with advanced disease (as above) were treated with PGN632 three
times a week in combination with daily ribavirin (3.25 mg/kg, i.p.) (Fig. 4b). This sub-optimal dose of ribavirin offered
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no protection by itself. However, when combined with PGN632, 50% of guinea pigs recovered from their infections
and survived, as compared to 20% in the group treated with PGN632 alone (Fig. 4b). This difference trended towards,
but did not reach, statistical significance (P=0.15). However, the difference in survival between the group treated with
PGN632  and  ribavirin,  and  the  group  treated  with  ribavirin  alone  was  statistically-significant  (p  ≤  0.0055).  Thus,
PGN632 appears to have additive anti-viral activity when combined with ribavirin.
3.6. Reduction of Viral Load in Tissues From Animals Treated With PGN632
Guinea pigs were treated with PGN632 on day 4 after infection, when they showed signs of advanced disease, and
were treated again on day 7. Animals were sacrificed ten days post-infection, and the virus load in blood and various
tissues  was  determined.  The  virus  load  in  the  blood  was  reduced  by  50-fold  relative  to  the  group  of  animals  that
received erbituximab. However, there were no significant reductions of viral load in the liver, lungs, kidneys, or hearts
of animals treated with PGN632 as compared to erbituximab recipients and the virus load in the spleen was elevated.
Bavituximab recipients also showed no significant reductions in virus load in these tissues (Fig. 5a). In contrast, in the
group of animals sacrificed on day 14, after 3 treatments, there was a 500-fold reduction in virus load in the blood, and
a 10-fold reduction in virus load in the liver, lung, kidney, and heart relative to erbituximab-treated animals (P<0.0001).
Bavituximab also reduced the virus load in blood and tissues, but to a somewhat lesser extent than did PGN632 (Fig.
5b). Virus load in the spleen was not reduced by either PGN632 or bavituximab treatment, probably because the spleen
is a major site of clearance of opsonized virus from the blood.
Fig. (5). PGN632 treatment reduced the virus load in guinea pigs infected with Pichinde virus. (a) Virus load in tissues on day 10:
Guinea pigs were infected with 105 PFU of virus and were treated with PGN632 (6 mg/kg, i.p.) on day 4 and again on day 7. The
guinea pigs were sacrificed on day 10. The histograms show virus load in PFU/g in the tissues. (b) Virus load in tissues on day 14:
Guinea pigs were infected with 105 PFU of virus and were treated with PGN632 (6 mg/kg, i.p.) on days 4, 7, and 10. They were
sacrificed  on  day  14.  The  histograms  show  PFU/g  in  the  tissues.  Bavituximab  treatment  was  given  as  a  positive  control,  and
erbituximab as a negative control. Columns, mean PFU per gram of tissue (n=3); bars, S.D.
3.7. PGN632 Causes Opsonization and Clearance of Pichinde Virus, and Induces Antibody-Dependent Cellular
Cytotoxicity (ADCC) of Virus-Infected Cells
We examined the mechanisms by which PGN632 rescued animals dying from Pichinde virus infections. First, we
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determined whether PGN632 was able to induce direct neutralization of Pichinde virus. Vero cells were infected with
Pichinde virus (MOI = 4) in the presence of PGN632, bavituximab or erbituximab. PGN632 reduced the yield of virus
only slightly (3-fold) and not significantly (Fig. 6a).  Bavituximab also reduced virus yield by 3-fold. Thus, neither
PGN632 nor bavituximab are neutralizing antibodies.
Fig. (6). Mechanism of anti-viral effects of PGN632. (a) Lack of neutralization of virus. P388D1 cells were infected with Pichinde
virus at an moi of 4 in the presence of antibody and β2GP1 (100µg/ml each). Cells and supernatants were collected on day 3, and
virus quantified by plaque assay. Columns, average PFU/ml; bars, S.D. In all the above studies, bavituximab was used as a positive
control and erbituximab as a negative control. PGN632 and bavituximab only reduce virus burden by 3-fold (not significant). (b)
Significant lack of Pichinde virus antigen-specific proliferative responses. Splenocytes were collected from antibody-treated animals
(n=3) 14 days after infection, and were stimulated in the presence of either virus or mock antigen, and their ability to incorporate
3[H]-thymidine was determined. Antibody therapy did not significantly increase the stimulation index. Columns, average stimulation
index (n=3); bars, S.D. (c) Opsonization of Pichinde virus. Whole blood samples were collected from animals (n=3) that had been
treated with antibody one day after infection, and virus quantified by plaque assay. Columns, average PFU/ml; bars, S.D. (d) ADCC
of virus-infected cells. Primary guinea pig fibroblasts in tissue culture were infected with Pichinde virus and, 48 hrs later, were co-
cultured with primary guinea pig peritoneal macrophages in the presence of PGN632. Lysis was determined by quantifying lactate
dehydrogenase (LDH) release. PGN632 induced specific lysis of virus-infected cells. Columns, average percentages (n=3); bars, S.D.
Next,  virus-specific  humoral  immune  responses  to  Pichinde  virus  were  assessed  in  guinea  pigs  that  had  been
infected with virus 14 days earlier, and then treated with PGN632, bavituximab or erbituximab as above. The day 14
time  point  was  selected  because  this  is  the  time  at  which  differences  in  survival  became  apparent.  There  were  no
significant  differences  in  levels  of  anti-Pichinde  virus  antibodies  in  the  PGN632  or  bavituximab-treated  animals
compared to erbituximab treated animals (results not shown). Similarly, splenocytes taken from guinea pigs that had
been sacrificed 14 days after infection and treated with PGN632 or bavituximab showed no significant proliferative
responses  to  Pichinde  antigens  compared  with  splenocytes  from  erbituximab-treated  guinea  pigs  (Fig.  6b)  Thus,
induction of humoral or cellular immunity does not appear to explain the survival of PGN632-treated animals.
We  determined  whether  antiviral  activity  could  be  due  to  opsonization  of  virus  by  PGN632  and  subsequent
clearance  by  the  reticuloendothelial  system.  Guinea  pigs  were  infected  with  Pichinde  virus  and  treated  i.p.  with
PGN632, bavituximab or erbituximab (6 mg/kg). Treatment with either PGN632 or bavituximab reduced the levels of
circulating virus in the blood by 10 to 15-fold (P<0.01) relative to animals treated with erbituximab (Fig. 6c). Thus,
opsonization of virus may contribute to the better survival of PGN632-treated guinea pigs.
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PGN632 and bavituximab efficiently mediated lysis of infected primary guinea pig fibroblasts by primary guinea pig
macrophages in vitro whereas erbituximab did not (P < 0.0001). PGN632 and bavituximab were equally effective at
mediating ADCC (Fig. 6a) Thus, ADCC by innate immune cells likely contributed to the anti-viral action of PGN632.
4. DISCUSSION
The use of antibodies as novel therapeutics against  infectious diseases has gained traction in recent years as an
effective way to combat invasive pathogens. Synagis (palivizumab) is a humanized monoclonal antibody that has been
approved  for  the  treatment  of  respiratory  syncytial  virus  [25].  Numerous  other  monoclonal  antibodies  are  being
developed for the treatment of a variety of viral diseases [12]. The PS-targeting chimeric antibody, bavituximab, has
been tested in clinical trials in patients co-infected with hepatitis C virus and human immunodeficiency virus [9], and
has demonstrated a capacity to bind other virally-infected cells and virions, including Ebola virus in vitro [27]. During
the clinical trials, bavituximab therapy appeared safe and well tolerated, and reductions were observed in virus load in
the  blood.  In  the  present  study,  we examined a  new,  fully  human PS-targeting  monoclonal  antibody,  PGN632,  for
antiviral activity in guinea pigs with advanced hemorrhagic arenavirus infections.
We recently identified PS as a generic marker of virus-infected cells and enveloped virions [4]. In uninfected cells,
PS is sequestered to the inner leaflet of the plasma membrane under normal physiological conditions [7, 13]. Soon after
virus infection (4 hours in Pichinde virus infected cells), PS becomes translocated to the outer surface of the cells [4].
Translocation could be due to activation of the cells by the virus and elevations of intracellular Ca2+ that activate PS
exporters  while  simultaneously  inhibiting  the  major  PS  importers,  the  aminophospholipid  translocases  [14,  15].
Alternatively,  translocation  could  be  related  to  pre-apoptotic  changes  [16].  Importantly,  virions  that  egress  from
infected cells have exposed PS on their outer envelope surface. Acquisition of exposed PS appears to be a common
feature of many enveloped viruses, including vesicular stomach virus [4], cytomegalovirus [4, 17], influenza [4], HIV-1
[18], vaccinia virus [19], and HSV [20]. Enveloped viruses that egress through the plasma membrane may acquire PS
from  raft-like  structures  which  are  enriched  for  PS  [21].  Viruses  that  acquire  their  envelope  from  intracellular
organelles, such as herpesviruses, may bud into vesicles that have not yet attained membrane asymmetry, or have lost
lipid asymmetry as a consequence of the viral infection. Because anionic phospholipids on virus-infected cells are host-
derived and independent of the viral  genome, the acquisition of drug resistance could be less of a problem for PS-
targeted antivirals than for agents that target virus-encoded components of the virus [24].
The PGN632 antibody has very similar phospholipid specificity to bavituximab, in that both antibodies recognize
anionic phospholipids, including PS. Both anti-PS antibodies produced indistinguishable staining patterns on Pichinde
virus-infected cells. PS is likely to be the major anionic phospholipid to become exposed on virus-infected cells since it
is the most abundant, and it is the lipid whose asymmetry is most tightly regulated. However, it is possible that there is
also exposure of the more-minor anionic phospholipids, including PI, PA and PG, which would also be detected by the
antibodies. The major differences between PGN632 and bavituximab are: 1) PGN632 is human whereas bavituximab is
chimeric and theoretically could induce antibodies against mouse determinants in patients and; 2) PGN632 binds to PS
directly, without the need for the β2GP1 cofactor protein, which avoids possible depletion of β2GP1 in patients.
PGN632 treatment of guinea pigs with advanced Pichinde virus infections protected 20% of animals from death and
reduced virus load in tissues. When combined with low-dose ribavirin, 50% of animals were protected, which would be
expected for drugs with non-overlapping mechanisms of protection. We previously reported that 50% of guinea pigs
could  be  protected  from death  by  treatment  with  bavituximab  alone,  a  higher  percentage  than  has  observed  in  the
present studies. It is possible that these differences relate to the much higher virus inoculum used to infect the animals
in the present study. It could also relate to the outbred nature of the guinea pig and genetic non-identity in the two
studies. We chose to use the i.p. route for administration of the PGN632 antibody, as we had previously used this same
route in our initial studies with bavituximab as an antiviral agent [4]. It is possible that better levels of protection could
have  been  achieved  if  the  antibody  had  been  delivered  using  the  intravenous  (i.v.)  route  however,  this  is  a  time-
intensive procedure that was beyond the scope of the current project. It has been shown that catheterized guinea pigs
infected with Ebola virus are readily-available for blood draws and sample administration but, to date, no data exists
that  shows  i.v.  administration  of  anti-PS  antibodies  would  achieve  any  improvement  over  i.p.  injection  within  the
context of arenavirus infections [27]. In humans infected with Lassa virus (another arenavirus that causes hemorrhagic
fever), survival correlates with virus levels in the blood. Patients having virus levels below 106 pfu/ml generally survive
[1]. Indeed, clinical analysis of 137 samples of human patients infected with Lassa virus showed that, in the cases where
Lassa virus infection was fatal, nearly all samples were viremic, with titers ranging from 103-108 TCID50/ml [26]. In the
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present studies, both PGN632 and bavituximab held the viremia in the guinea pigs below this level. Ribavirin is the
only drug currently approved for treating human VHF, but is toxic when administered at doses that are considered to be
efficacious, and it must be given early in infection to be effective [2, 22]. Combination with PGN632 or bavituximab
may allow for reducing the dose of ribavirin to non-toxic levels, without sacrificing efficacy.
Two mechanisms appear to explain the antiviral activity of PGN632: (1) opsonization of virus by the antibody; and
(2) the induction of antibody dependent cellular cytotoxicity (ADCC) of virally-infected cells [4]. PGN632 thus appears
to act through the same mechanisms as bavituximab. A single dose of PGN632 reduced circulating Pichinde virus in the
blood of infected guinea pigs by 10 to 15-fold. PGN632 also efficiently mediated the lysis of virally-infected guinea pig
fibroblasts by primary guinea pig macrophages by ADCC. Together, these data suggest that protection is the result of
limiting virus spread, either by direct clearance of virus from the blood, or by indirect clearance of virally infected cells
in an antibody-dependent manner. PGN632, like bavituximab, was unable to neutralize infectivity of Pichinde virus.
Thus, coating Pichinde virions with PGN632 does not obstruct virus entry. However, in an earlier study on HIV-1, we
found that PGN632 inhibited CCR5-tropic primary HIV-1 isolates from infecting human peripheral blood mononuclear
cells in vitro.  The mechanism was that PGN632 induced β-chemokine production which blocked the R5 coreceptor
[23]. Viral PS also is required for vaccinia virus infectivity [19]. Thus, it is possible that PS-targeting antibodies will
have additional mechanisms of action with different viruses.
CONCLUSION
In  conclusion,  using  antibodies  to  target  exposed  PS  on  virus-infected  cells  and  virions  shows  promise  as  an
antiviral  strategy.  Because  the  antibodies  act  by  different  mechanisms,  they  should  be  used  in  combination  with
conventional antiviral agents. Other strategies for exploiting the exposure of PS on virus-infected cells and/or virus
envelopes can be envisioned: antibodies, peptides or small molecules that target exposed anionic phospholipids might
be used to deliver or direct agents that interfere with host cell or viral metabolism, or recruit immune effector cells.
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